Taiwan News12d
U.S. FDA approves Celltrion's OMLYCLO® (omalizumab-igec) as the first and only biosimilar with interchangeability designation referencing XOLAIR®
OMLYCLO® (omalizumab-igec) is the first and only omalizumab biosimilar approved by the FDA Regulatory approval for interchangeability was supported by positive phase III data demonstrating comparable ...
Yahoo Finance24d
Humacyte Announces Commercial Launch of Symvess™ (acellular tissue engineered vessel-tyod) for Extremity Vascular Trauma
DURHAM, N.C., Feb. 26, 2025 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company developing universally implantable ...
The American Journal of Managed Care26d
EU Approves Self-Administered Rozanolixizumab for Myasthenia Gravis
Common adverse reactions include headache, diarrhea, and pyrexia, with contraindications for hypersensitivity to the active substance or excipients. With 2 new self-administration methods ...